| abstract |
New formulations for N- [4- (5H-pyrrolo [2,1-c] [1,4] benzodiazepin-10 (11H) ylcarbonyl) -3-chlorophenyl] -5-fluoro-2-methyl are described. benzamide or a pharmaceutically acceptable salt thereof, and processes for their preparation, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acids and / or polyvinylpyrrolidone, and optionally one or more pharmaceutically acceptable preservatives or antioxidants. |